Pneumococcal vaccine development

Expert Review of Vaccines

Volumn 3, Issue 5, 2004, Pages 597-604

  Poolman, Jan T ^a  

^a GSK   (Belgium)

Author keywords

Immune mechanisms; Pneumococcal conjugate vaccine; Pneumococcal immunization; Pneumococcal polyssaccharide vaccine; Pneumococcal proteins

Indexed keywords

BACTERIAL PROTEIN; CELL SURFACE PROTEIN; MULTIVALENT PNEUMOCOCCAL POLYSACCHARIDE VACINE; PNEUMOCOCCAL HISTIDINE TRIAD PROTEIN; PNEUMOCOCCAL SURFACE PROTEIN A; PNEUMOCOCCUS VACCINE; PNEUMOLYSIN; POLYSACCHARIDE; PROTEIN CBPA; UNCLASSIFIED DRUG;

BACTEREMIA; CHILDHOOD DISEASE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; HERD IMMUNITY; HUMAN; IMMUNIZATION; LOBAR PNEUMONIA; OTITIS; PNEUMONIA; PRIORITY JOURNAL; REVIEW; STREPTOCOCCUS INFECTION; TREATMENT OUTCOME; VACCINATION;

ADULT; AGE FACTORS; AGED; ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; CHILD, PRESCHOOL; DRUG DESIGN; HUMANS; MENINGOCOCCAL VACCINES; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; PRODUCT SURVEILLANCE, POSTMARKETING; RANDOMIZED CONTROLLED TRIALS; STREPTOCOCCUS PNEUMONIAE; VACCINATION; VACCINES, CONJUGATE;

EID: 7444226357     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.3.5.597     Document Type: Review

References (86)

1. Austrian R. Pneumococci. In: Microbiology. Third Edition. Davis BD, Dulbecco R, Eisen HN, Ginsberg HS (Eds). Harper and Row, NY, USA, 595-606 (1980).
2. Brown JS, Hussel T, Gilliland SM et al. The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice. PNAS 99, 16969-16974 (2002).
3. Butcher S, Chachel H, Lord JM. Ageing and the neutrophil: no appetite for killing? Immunology 100, 411-416 (2000).
4. Musher DM, Phan HM, Watson DA, Baughn DA. Antibody to capsular polysaccharide of Streptococcus pneumoniae at the time of hospital admission for pneumococcal pneumonia. J. Infect. Dis. 182, 158-167 (2000).
5. Romero-Steiner S, Musher DM, Cetron MS et al. Reduction in functional activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin. Infect. Dis. 29, 281-288 (1999).
6. Artz AS, Ershler WB, Longo DL. Pneumococcal vaccination and revaccination of older adults. Clin. Microbiol. Rev. 16, 308-318 (2003).
7. Törling J, Hedlund J, Bossen-Konradsen H, Ortqvist A. Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia. Vaccine 22, 96-103 (2003).
8. Kruetzmann S, Rosado MM, Weber H et al. Human immunoglobulin M memory B-cells controlling Streptococcus pneumoniae infections are generated in the spleen. J. Exp. Med. 197, 939-945 (2003).
9. Haynes L, Eaton SM, Burns EM, Rincon M, Swain SL. Inflammatory cytokines overcome age-related defects in CD4 cell responses in vivo. J. Immun. 172, 5194-5199 (2004).
10. Knapp S, Hareng L, Rijneveld AW et al. Activation of neutrophils and inhibition of the pro-inflammatory cytokine response by endogenous granulocyte colony-stimulating factor in murine pneumococcal pneumonia. JID 189, 1506-1514 (2004).
11. Kadioglu A, Coward W, Colston MJ, Hewitt CRA, Andrew PW. CD4 T-lymphocyte interactions with pneumolysin and pneumococci suggest a crucial protective role in the host response to pneumococcal infection. Infect. Immun. 72, 2689-2697 (2004).
12. Fedson DS, Liss C. Precise answers to the wrong question: prospective clinical trials and the meta-analyses of pneumococcal vaccine in elderly and high-risk adults. Vaccine 22, 927-946 (2003). Reviews the clinical trials and clinical impact of the pneumococcal polysaccharide vaccine (PPV) in adults.
13. Dear K, Holden J, Andrews R, Tatham D. Vaccines for preventing pneumococcal infection in adults. The Cochrane Library, 1. John Wiley & Sons, Chichester, UK (2004).
14. Hsu KK, Pelton SI. Heptavalent pneumococcal conjugate vaccine: current and future impact. Expert Rev. Vaccines 2, 619-631 (2003).
15. Klugman KP, Madhi SA, Huebner RE et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N. Engl. J. Med. 349, 1341-1348 (2003).
16. Black S, Shinefield H, Fireman B et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr. Infect. Dis. J. 19, 187-195 (2000). Describes the impact of pneumococcal conjugate vaccine (PCV) on pediatric invasive pneumococcal diseases.
17. O'Brien KL, Moulton LH, Reid R et al. Efficacy and safety of 7-valent conjugate pneumococcal vaccine in American Indian children: group randomized trial. Lancet 362, 355-361 (2003).
18. Whitney CG, Farley M, Hadler J et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N. Engl. J. Med. 348, 1737-1746 (2003). Describes the PCV postlicensure impact, including the nonimmunized age group.
19. Black SB, Shinefield H, Baxter R et al. Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr. Infect. Dis. J. 23, 485-489 (2004). Describes the antibody correlates of protection in relation to pediatric PCV.
20. Jódar L, Butler J, Carlone G et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccines formulations for use in infants. Vaccine 21, 3265-3272 (2003).
21. Jackson LA, Neuzil KM, Yu O et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N. Engl. J. Med. 348, 1747-1755 (2003). Describes the limitations of PPV with regards to adult pneumococcal pneumonia.
22. Honkanen PO, Keistinen T, Miettinen L et al. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older. Vaccine 17, 2493-2500 (1999).
23. Nichol KL, Baken L, Wuorenma J, Nelson A. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Arch. Intern. Med. 159, 2437-2442 (1999).
24. Wagner C, Popp W, Posch M, Vlasich C, Rosenberger-Spitzy A. Impact of pneumococcal vaccination on morbidity and mortality of geriatric patients: a case-controlled study. Gerontology 49, 246-250 (2003).
25. Zysk G, Bethe G, Nau R et al. Immune response to capsular polysaccharide and surface proteins of Streptococcus pneumoniae in patients with invasive pneumococcal disease. J. Infect. Dis. 187, 330-333 (2003).
26. Scott A, Obiero J, Marsh K. Susceptibility to pneumococcal pneumonia is determined by unresponsiveness to pneumococcal polysaccharides in general rather than by serotype-specific immunodeficiency. ISPPD Abstract (2002).
27. Hedlund J, Örtqvist A, Konradsen HB, Kalin M. Recurrence of pneumonia in relation to the antibody response after pneumococcal vaccination in middle-aged and elderly adults. Scand. J. Infect. Dis. 32, 281-286 (2000).
28. Rubins JB, Alter M, Loch J, Janoff EN. Determination of antibody responses of elderly adults to all 23 capsular polysaccharides after pneumococcal vaccination. Infect. Immun. 67, 5979-5984 (1999).
29. Yee AMF, Phan HM, Zuniga R, Salmon JE, Musher DM. Association between FcγRIIa-R131 allotype and bacteremic pneumococcal pneumonia. Clin. Infect. Dis. 30, 25-28 (2000).
30. Smithson SL, Srivastava N, Westerink MAJ. Differential V gene expression detected in the immune response to Streptococcus pneumoniae capsular polysaccharide between elderly and young adults. Hybridoma and Hybridomics 21, 19-24 (2002).
31. Abraham-Van Parijs B. Review of pneumococcal conjugate vaccine in adults: implications on clinical development. Vaccine 22, 1362-1371 (2004). Reviews adult immunogenicity studies with PCV.
32. Musher DM, Groover JE, Watson DA, Rodriguez-Barradas MC, Baugh RE. IgG responses to protein-conjugated pneumococcal capsular polysaccharides in persons who are genetically incapable of responding to unconjugated polysaccharides. Clin. Infect. Dis. 27, 1487-1490 (1998).
33. Zielen S, Bürning I, Strnad N, Reichenbach J, Hofmann D. Immunogenicity and tolerance of a 7-valent pneumococcal conjugate vaccine in nonresponders to the 23-valent pneumococcal vaccine. Infect. Immun. 68, 1435-1440 (2000).
34. Soininen A, Seppälä I, Nieminen T, Eskola J, Käythy H. IgG subclass distribution of antibodies after vaccination of adults with pneumococcal conjugate vaccines. Vaccine 17, 1889-1897 (1999).
35. Vernacchio L, Romero-Steiner S, Martinez JE et al. Comparison of opsonophagocytic assay and IgG ELISA to assess responses to pneumococcal polysaccharide and pneumococcal conjugate vaccines in children and young adults with sickle-cell disease. J. Infect. Dis. 181, 1162-166 (2000).
36. Shelly MA, Schiff G, Wernette C et al. Evaluation of a 9-valent CRM197 conjugated pneumococcal polysaccharide vaccine in elderly adults. ICAAC Poster G-902a (2003).
37. Fry AM, Zell ER, Schuchat A, Butler JC, Whitney CG. Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly. Vaccine 21, 303-311 (2002).
38. Jackson LA, Benson P, Sneller VP et al. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA 281, 243-248 (1999).
39. Concepcion N, Frasch C. Pneumococcal Type 22F polysaccharide adsorption improves the specificity of a pneumococcal polysaccharide enzyme-linked immunosorbent assay. Clin. Diagn. Lab. Immunol. 8, 266-272 (2001). Describes the benefits of using antipneumococcal polysaccharide enzyme-linked immunosorbent assay (ELISA) including 22F inhibition.
40. Lazou-Ahren I, Janson H, Forsgren A, Riesbeck K. Protein D expression promotes the adherence and internalization of nontypeable Haemophilus influenzae into human monocytic cells. Microb. Pathog. 31, 151-158 (2001).
41. Bogaert D, De Groot R, Hermans PWM. Streptococcus pneumoniae colonization: the key to pneumococcal disease. Lancet Inject. Dis. 4, 144-154 (2004).
42. Swiatlo E, Champlin FR, Holman SC, Wilson WW, Watt JM. Contribution of choline-binding proteins to cell surface properties of Streptococcus pneumoniae. Infect. Immun. 70, 412-415 (2002).
43. Balachandran P, Brooks-Walter A, Virolainen-Julkunen A, Hollingshead SK, Briles DE. Role of pneumococcal surface protein C in nasopharyngeal carriage and pneumonia and its ability to elicit protection against carriage of Streptococcus pneumoniae. Infect. Immun. 70, 2526-2534 (2002).
44. Weiser JN, Bae D, Fasching C et al. Antibody-enhanced pneumococcal adherence requires IgA1 protaese. Proc. Natl Acad. Scill. USA 100, 4215-4220 (2003).
45. Tong HH, Blue LE, James MA, De Mark TF. Evaluation of the virulence of a Streptococcus pneumoniae neuraminidase-deficient mutant in nasopharageal colonization and development of otitis media in the chinchilla model. Infect. Immun. 68, 921-924 (2000).
46. Kadioglu A, Taylor S, Iannelli F et al. Upper and lower respiratory tract in infection by Streptococcus pneumoniae is affected by pneumolysin deficiency and differences in capsule type. Infect. Immun. 70, 2886-2890 (2002).
47. Weiser JN, Lapoor M. Effect of intrastrain variation in the amount of capsular polysaccharide on genetic transformation of Streptococcus pneumoniae: implications for virulence studies of encapsulated strains. Infect. Immun. 67, 3690-3692 (1999).
48. Ghaffar F, Friedland IR, McCracken CH Jr. Dynamics of nasopharyngeal colonization by Streptococcus pneumoniae. Pediatr. Infect. Dis. J. 18, 638-646 (1999).
49. Greenwood B. The epidemiology of pneumococcal infection in children in the developing world. Philos. Trans. R. Soc. Lond. B: Biol. Sci. 354, 777-785 (1999).
50. Simell B, Korkeila M, Pursiaenen H, Kilpi TM, Käihty H. Pneumococcal carriage and otitis media induce salivary antibodies to pneumococcal surface adhesin A, pneumolysin and pneumococcal surface protein A in children. J. Infect. Dis. 183, 887-896 (2001).
51. Kilpi T, Terhi MD, Herva E et al. Bacteriology of acute otitis media in a cohort of Finnish children followed for the first 2 years of life. Pediatr. Infect. Dis. J. 20, 654-662 (2001).
52. Mc Cool TL, Gate TR, Moy G, Weiser JN. The immune response to pneumococcal proteins during experimental human carriage. J. Exp. Med. 195, 359-365 (2003).
53. Dagan R, Givon-Lavi N, Zamir O, Fraser D. Effect of a nonavalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus pneumoniae in daycare centers. Pediatr. Infect. Dis. J. 22, 532-540 (2003).
54. Klugman BCP. Efficacy of pneumococcal conjugate vaccines and their effect on carriage and antimicrobial resistance. Lancet Infect. Dis. 1, 85-91 (2001).
55. Eskola J, Kilpi T, Palmu A et al. Efficacy of a pneumococal conjugate vaccine against acute otitis media. N. Engl. J. Med. 344, 403-409 (2001). Describes the impact of PCV on pediatric otitis including serotype replacement.
56. Kilpi T, Ahman H, Jokinen J et al. Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children. Clin. Infect. Dis. 37, 1155-1164 (2003).
57. Veenhoven R, Bogaert D, Uiterwaal C et al. Effect of conjugate pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media: a randomized trial. Lancet 361, 2189-2195 (2003).
58. Kaplan SL, Mason EO, Wald ER et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics 113, 443-449 (2004).
59. Straetemans M, Sanders EM, Veenhoven RH et al. Review of randomized controlled trials on pneumococcal vaccination for prevention of otitis media. Pediatr. Infect. Dis. J. 22, 515-524 (2003).
60. Feikin DR, Klugman KP. Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. Clin. Infect. Dis. 35, 547-555 (2002).
61. Sandgren A, Sjöström K, Olsson-Liljequist B et al. Effect of clonal and serotype-specific properties on the invasive capacity of Streptococcus pneumoniae. J. Infect. Dis. 189, 785-796 (2004).
62. Brueggemann AB, Griffiths DT, Meats E et al. Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype-and clone-specific differences in invasive disease potential. J. Infect. Dis. 187, 1424-1432 (2003).
63. Hanaga WP, Auranen K, Syrjänen R et al. Ability of pneumococcal serotypes and clones to cause acute otitis media: implications for the prevention of otitis media by conjugate vaccines. Infect. Immun. 72, 76-81 (2004).
64. Wizeman TM, Heinrichs JH, Adamou et al. Use of a whole genome approach to identify molecules affording protection against Streptococcus pneumoniae infection. Infect. Immun. 69, 1593-1598 (2001).
65. Ren B, Szalai AJ, Hollingshead SK, Briles DE. Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface. Infect. Immun. 72, 114-122 (2004).
66. Ren B, Szalai AJ, Thomas O, Hollingshead SK, Briles DE. Both family 1 and family 2 PspA proteins can inhibit complement deposition and confer virulence to a capsular serotype 3 strain of Streptococcus pneumoniae. Infect. Immun. 71, 75-85 (2003).
67. Briles DE, Hollingshead SK, Paton JC et al. Immunizations with pneumococcal surface protein A and pneumolysin are protective against pneumonia in a murine model of pulmonary infection with Streptococcus pneumoniae. J. Infect. Dis. 188, 339-348 (2003).
68. Kagioglu A, Andrew PW, The innate immune response to pneumococcal lung infection: the untold story. Trends Immunol. 25, 143-149 (2004).
69. Alcantara RB, Preheim LC, Gentry-Nielsen MJ. Pneumolysin-induced complement depletion during experimental pneumococcal bacteremia. Infect. Immun. 69, 3569-3575 (2001).
70. Musher DM, Phan HM, Baughn RE. Protection against bacteremic pneumococcal infection by antibody to pneumolysin. J. Infect. Dis. 183, 827-830 (2001).
71. Huo Z, Spencer O, Miles J et al. Antibody responses to pneumolysin and to pneumococcal capsular polysaccharide in healthy individuals and Streptococcus pneumoniae infected patients. Vaccine 22, 1157-1161 (2004).
72. Adamou JE, Heinrichs JH, Erwin AL et al. Identification and characterization of a novel family of pneumococcal proteins that are protective against sepsis. Infect. Immun. 69, 949-958 (2001).
73. Zhang Y, Masi AW, Barniak V et al. Recombinant PhpA protein, a unique histidine motif-containing protein from Streptococcus pneumoniae protects mice against intranasal pneumococcal challenge. Infect. Immun. 69, 3827-3836 (2001).
74. Hamel J, Charland N, Pineau I et al. Prevention of pneumococcal disease in mice immunized with conserved surface-accessible proteins. Infect. Immun. 72, 2659-2670 (2004).
75. Jarva H, Janulczyk R, Hellwage J, Zipfel PF, Björck L, Meri S. Streptococcus pneumoniae evades complement attack and opsonophagocytosis by expressing the pspC locus-encoded Hic protein that binds short consensus repeats 8-11 of factor H. J. Immunol. 168, 1886-1894 (2001).
76. Duthy TG, Ormsby RJ, Giannakis E et al. The human complement regulator factor H binds pneumococcal surface protein PspC via short coknsensus repeats 13 to 15. Infect. Immun. 70, 5604-5611 (2002).
77. Ianelli F, Oggioni MR, Pozzi G. Allelic variation in the highly polymorphic locus pspC of Streptococcus pneumoniae. Gene 28, 63-71 (2002).
78. Murdoch C, Read RC, Zhang Q, Finn A. Choline-binding protein A of Streptococcus pneumoniae elicits chemokine production and expression of intercellular adhesion molecule 1 (CD54) by human alveolar epithelial cells. J. Infect. Dis. 186, 1253-1260 (2002).
79. Ogunniyi AD, Woodrow MC, Poolman JT, Paton JC. Protection against Streptococcus pneumoniae elicited by immunization with pneumorysin and CbpA. Infect. Immun. 69, 5997-6003 (2001).
80. Balanchandran P, Brooks-Walter A, Virolainen-Julkunen A, Hollilngshead SK, Briles DE. Role of pneumococcal surface protein C in nasopharyngeal carriage and pneumonia and its ability to elicit protection against carriage of Streptococcus pneumoniae. Infect. Immun. 70, 2526-2534 (2002).
81. Briles DE, Paton JC, Sampson JS et al. Intranasal immunization of mice with a mixture of the pneumococcal proteins PspA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae. Infect. Immun. 68, 796-800 (2000).
82. Malley R, Lipsitch M Stack A et al. Intranansal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumocicci. Infect. Immun. 69, 4870-4873 (2001).
83. Long JP, Tong HH, DeMaria TF. Immunization with native or recombinant Streptococcus pneumoniae neuraminidase affords protection in the chinchilla otitis model. Infect. Immun. 72, 4309-4313 (2004).
84. Mi QS. Highly reduced protection against Streptococcus pneumoniae after deletion of a single heavy chain gene in mouse. Proc. Natl Acad. Sci. USA 97, 6031-6036 (2000).
85. Hausdorff WP. Invasive pneumococcal disease in children: geographic and temporal variations in incidence and serotype distribution. Eur. J. Pediatr. 161, S135-S139 (2002).
86. Schuchat A (Centers of Disease Control and Prevention). Presentation at the 4th International Symposium on Pneumococci and Pneumococcal Diseases, Helsinki, Finland, 9-13 May (2004).